X-linked agammaglobulinemia historical perspective

X-linked agammaglobulinemia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating X-linked agammaglobulinemia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Serology
Chest X Ray
CT
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
X-linked agammaglobulinemia historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of X-linked agammaglobulinemia historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on X-linked agammaglobulinemia historical perspective
CDC on X-linked agammaglobulinemia historical perspective
X-linked agammaglobulinemia historical perspective in the news
Blogs on X-linked agammaglobulinemia historical perspective
Directions to Hospitals Treating X-linked agammaglobulinemia
Risk calculators and risk factors for X-linked agammaglobulinemia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Historical Perspective

XLA was first characterized by Dr. Ogden Bruton in a ground-breaking research paper published in 1952 describing a boy unable to develop immunities to common childhood diseases and infections. Bruton's paper describes the first known immune deficiency. XLA is classified with other inherited (genetic) defects of the immune system, known as primary immunodeficiency disorders.